This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Study of LY3025876 in Healthy Volunteers

This study has been completed.
Information provided by (Responsible Party):
Eli Lilly and Company Identifier:
First received: February 3, 2012
Last updated: May 21, 2012
Last verified: May 2012
This trial is conducted in Singapore. The aim of this trial is to evaluate the safety and tolerability of the study drug in healthy people and investigate how much of the study drug gets into the blood stream and how long it takes the body to get rid of it. Information about any side effects that may occur will also be collected.

Condition Intervention Phase
Healthy Volunteers Drug: LY3025876 Drug: Placebo Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Basic Science
Official Title: A Single-Dose, Dose-Escalation Study to Determine the Safety, Tolerability, and Pharmacokinetics of LY3025876 in Healthy Subjects

Further study details as provided by Eli Lilly and Company:

Primary Outcome Measures:
  • Number of Participants with one or more drug related Adverse Events or any Serious Adverse Events [ Time Frame: Baseline up to 28 days after administration of study drug ]

Secondary Outcome Measures:
  • Pharmacokinetics : Area under the concentration curve (AUC) of LY3025876 [ Time Frame: Up to 48 hours after administration of study drug ]
  • Pharmacokinetics : Maximum concentration (Cmax) of LY3025876 [ Time Frame: Up to 48 hours after administration of study drug ]
  • Number of Participants developing anti-LY3025876 antibodies [ Time Frame: Up to 28 days after administration of study drug ]

Estimated Enrollment: 63
Study Start Date: February 2012
Study Completion Date: May 2012
Primary Completion Date: May 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo
0.9% sodium chloride given as a single subcutaneous (SC) injection
Drug: Placebo
Given as a SC injection
Experimental: LY3025876
Single escalating doses of LY3025876 given as SC injections
Drug: LY3025876
Given as a SC injection


Ages Eligible for Study:   21 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Must be either a healthy male or a healthy female who cannot become pregnant
  • Have a body mass index (BMI) of 18.5 to 40.0 kg/m^2, inclusive, at screening

Exclusion Criteria:

  • Are allergic to LY3025876 or related compounds
  • Have a history of significant disease that may affect the actions of drugs or may pose a risk when taking the study medication
  • Have a history of developing allergies, asthma, severe drug allergies (symptoms including, but not limited to, itching, red rashes, sores on the skin, scaling and shedding of skin), allergies or reactions to more than one drug, or have had bad reactions to skin creams containing corticosteroids. Corticosteroids are mainly used to control inflammation.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01528124

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Singapore, Singapore, 117597
Sponsors and Collaborators
Eli Lilly and Company
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company
  More Information

Responsible Party: Eli Lilly and Company Identifier: NCT01528124     History of Changes
Other Study ID Numbers: 14346
I6D-FW-SMRA ( Other Identifier: Eli Lilly and Company )
Study First Received: February 3, 2012
Last Updated: May 21, 2012 processed this record on August 18, 2017